[Raynaud phenomenon as adverse effect of ADHD treatment].
D018759:Adrenergic Uptake Inhibitors / Q000009:adverse effects; D000069445:Atomoxetine Hydrochloride; D001289:Attention Deficit Disorder with Hyperactivity / Q000188:drug therapy*; D000697:Central Nervous System Stimulants / Q000009:adverse effects*; D018765:Dopamine Uptake Inhibitors / Q000009:adverse effects; D006801:Humans; D008774:Methylphenidate / Q000009:adverse effects; D011437:Propylamines / Q000009:adverse effects; D011928:Raynaud Disease / Q000139:chemically induced*
D018759:Adrenergic Uptake Inhibitors; D000697:Central Nervous System Stimulants; D018765:Dopamine Uptake Inhibitors; D011437:Propylamines; D008774:Methylphenidate; D000069445:Atomoxetine Hydrochloride